Cardiovascular diseases are the number one cause of death worldwide and greatly impact
quality of life and medical costs. Enormous effort has been made in research to obtain new …

Heart failure (HF) management is challenging due to high clinical heterogeneity of this
disease which makes patients responding differently to evidence-based standard therapy …

Findings from clinical and biological studies are often not reproducible when tested in
independent cohorts. Due to the testing of a large number of hypotheses and relatively small …

Patients with heart failure continue to suffer adverse health consequences despite advances
in therapies over the past 2 decades. Identification of novel therapeutic targets that may …

A plethora of environmental and behavioral factors interact, resulting in changes in gene
expression and providing a basis for the development and progression of cardiovascular …

Non-small cell lung cancer (NSCLC) is a common and lethal malignancy. The carcinogenic
roles of lncRNA CALML3 antisense RNA 1 (CALML3-AS1) have been documented …

Epigenetic modifications influence gene expression programs ultimately dictating
physiological outcomes. In the past decades, an increasing body of work has demonstrated …

One of 5 people will develop heart failure over his or her lifetime. Early diagnosis and better
understanding of the pathophysiology of this disease are critical to optimal treatment. The …

When we encounter an unexpected critical health problem, a hospital's emergency
department (ED) becomes our vital medical resource. Improving an ED's timeliness of care …

Rationale: Only a small portion of the known heritability of cardiovascular diseases, such as
heart failure, can be explained based on single-gene mutations. Chromatin structure and …